MedTrace Logo

Rivaroxaban or Placebo for Extended Antithrombotic Prophylaxis After Laparoscopic Surgery for Colorectal Cancer.

NCT03055026 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 582

Last updated 2022-03-11

No results posted yet for this study

Summary

Rivaroxaban or placebo for extended antithrombotic prophylaxis after laparoscopic surgery for colorectal cancer: a randomized, double blind, placebo-controlled study.

Conditions

  • Prevention of Venous Thromboembolism

Interventions

DRUG

Rivaroxaban

Tablets

DRUG

Placebo

Tablets

Sponsors & Collaborators

  • University Of Perugia

    collaborator OTHER

  • Fadoi Foundation, Italy

    lead OTHER

Principal Investigators

  • Mauro Campanini · FADOI Foundation

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2017-05-03
Primary Completion
2021-07-09
Completion
2021-09-06

Countries

  • Italy

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03055026 on ClinicalTrials.gov